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Dr A. Marc Gillinov (Cleveland, Ohio). Pat, that was a great
study. These sorts of studies require tremendous patience, focus,
and determination, similar to the patience, focus, and determina-
tion you showed when you taught me how to do a maze procedure
almost 20 years ago, and thank you for that.
Paroxysmal AF is an uncommon subject of study in our field,
but it is a really common clinical problem, and what you are doing
is filling the knowledge gap. You have shown that treatment of PAF
is associated with decreased complications, increased freedom
from AF, and increased apparent long-term survival. I have only
2 questions, which I hope will guide me if I am in the operating
room on Monday and I have a patient with PAF.
The first question: which patients with PAF should receive
ablation?822 The Journal of Thoracic and Cardiovascular SurgDrMcCarthy. The decision-making really begins by consider-
ing the operation that the patient needs. If the left atrium is open, it
is easy and quick to add LA ablation, which these days I typically
perform with cryoablation. AF ablation is performed in nearly
100% of that patient group. However, if it is a patient who needs
coronary bypass or aortic valve replacement, especially if it is an
older patient, we tend to just do PVI.
Dr Gillinov. And that gets to my second question: which lesion
set? What is your favorite lesion set and would you alter it if the
patient had, for instance, highly symptomatic PAF? Would the
highly symptomatic patient push you toward a full Cox maze IV
and are there other factors, some that you have mentioned, that
would lead you to perform PVI alone?
Dr McCarthy. Young patients, AF symptomatic patients, and
a stroke history are the 3 clinical factors that really make us
more aggressive in how we treat AF. For that group of patients,
in particular, even if I am doing an aortic valve operation or coro-
nary bypass, I might open the left atrium and do a more complete
lesion set. If I am also doing a tricuspid, it is quick and easy to add
the right atrial lesions, and so you end up with a biatrial lesion set
in that group.
DrVinayBadhwar (Pittsburgh, Pa).Congratulations on awon-
derful presentation and a provocative addition to the published
data. When we are faced with surgically treating patients who
have concomitant PAF, it occasionally becomes an issue of defini-
tion. For example, a patient who reports palpitations or, perhaps,
has a remote electrocardiogram for the preoperative workup show-
ing they are actually not in AF.
For your study, did you have some rigor in the documentation or
definition of PAF?
DrMcCarthy.All the patients had to have documented electro-
cardiographic evidence that they had had AF in the past. We did
not accept clinical symptoms that suggested AF without electro-
cardiographic documentation. If we saw preoperative patients
with that history, we always sent them for a 48-hour Holter monitor
test before surgery just to be certain. Also, we have 2 AF nurses
whose full-time job is to help with the assessment of those patients
and perform the follow-up. Thus, they are pretty careful about get-
ting good data about preoperative AF, in accordance with the HRS
document.
Dr Takashi Nitta (Tokyo, Japan). I have 2 questions. First, how
many of the patients in the untreated AF group developed perma-
nent AF during your follow-up period?
Dr McCarthy. That is a good question. We were just recording
how many went into AF. We did not actually, in the present study,
determine whether they were still in PAF. We were just reporting
according to the HRS guidelines. However, we should be able to
tease that information out to see howmany progressed to persistent
or longstanding persistent AF.
Dr Nitta. Second, did you study the recurrence or progression
of mitral valve regurgitation in the untreated AF group, because
1 of the reasons for the poorer outcomes in the untreated group
might have been the progression or recurrence of mitral valve
regurgitation.
Dr McCarthy. I think you were asking, if we were treating for
coronary bypass or aortic valve disease, and we were not treating
for the mitral valve, was there some progression of mitral valve
disease, and, no, we did not include that in this study.ery c October 2013
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DDr Steven F. Bolling (Ann Arbor, Mich). Pat, a great study
as always. You did not really present the stroke data, although
you did state in the abstract that it was the same among all the
groups. I assume that was because it was pretty low. Did it
surprise you that in the untreated PAF group the later stroke
rate was not high?
DrMcCarthy.No. I think all those patients would have contin-
ued to takewarfarin. However, you are right, in the study, no differ-
encewas found in the stroke rate. The data continued out to 5 years.
It also was not a huge population of patients being followed up.
Dr Bolling. In the treated PAF group, I assume you took all the
appendages or dealt with the appendages. In the untreated group,
do you do anything with the appendage?
Dr McCarthy. In the untreated AF group, if we were there for
mitral disease, that was a very small number, we likely treated the
appendage. However, in the group with aortic valve or coronary
bypass, not necessarily, especially in reoperations.
Dr Bolling. And then the last question. How did you handle
warfarin in all the patients?
DrMcCarthy.We have a pretty strict protocol in how we man-
age warfarin and AF. At 3 months, the AF nurses obtain a Holter
monitor recording for every patient, and if they are free of AF
and free of AF symptoms, we stop their AADs, usually amiodar-
one. Then, we recheck them at 6 months after that has washed
out with another Holter monitor or pacemaker interrogation, and
only then will we consider stopping warfarin. We also use the
CHA2DS2-VASc to help guide whether to stop it.
Dr Niv Ad (Falls Church, Va). Excellent presentation. One
quick question because I might have overheard, but did you men-
tion that if you have an aortic valve or CABG you are reluctant to
open the left atrium, and if so, why, because we have shown, and
others have shown, that even if you perform a full Cox mazeThe Journal of Thoracic and Caprocedure on these patients you do not increase the risk of surgery
like any other procedure.
Dr McCarthy. I said we do it less often, especially in the PAF
patient population. It depends on the age of the patient and their
general condition. So, for instance, if it is an 89yearold patient
who has had 3 episodes of PAF before surgery, I will do a mini-
mally invasive aortic valve replacement, and I would not perform
a sternotomy and then open the left atrium to treat that. That has
just been our approach.
Dr Ad. The 1 potential hazard, especially with patients with
aortic stenosis, is that you open the gate for LA atypical flutter.
So, if the patient is too sick, perhaps just remove the appendage
and leave the rest as is and not set up for worse arrhythmia.
Dr McCarthy. So you are saying if you do just PVI, you might
set them up for atrial flutter?
Dr Ad. Yes.
Dr McCarthy. That is a group of patients that we would not
necessarily treat at all in that older patient population, but we
did not observe that in the PVI-treated population.
Dr Ralph J. Damiano (St. Louis, Mo). If I understood it cor-
rectly, you reported your results as FFAF at the last follow-up visit.
Dr McCarthy. Without AADs, yes.
Dr Damiano. The present guidelines have suggested that suc-
cess should be defined as FFAF and AADs at 12 months. Thus,
if you considered the data that way, which is a little more rigorous,
because the last follow-up visit is very hard to know, it might be 1
month, 3 months, we do not know, but does that change any of your
conclusions?
Dr McCarthy. The last follow-up visit averaged 2.8 years in
this group, and in the report, actually we do include all the various
combinations. However, in a 10-minute talk I could not show all
the various combinations.rdiovascular Surgery c Volume 146, Number 4 823
